PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
47.21%
EBIT growth above 1.5x AGEN's 17.04%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
40.44%
Operating income growth above 1.5x AGEN's 17.80%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
42.50%
Net income growth 1.25-1.5x AGEN's 30.92%. Bruce Berkowitz would see if strategic cost cutting or product mix explains this difference.
40.54%
EPS growth 1.25-1.5x AGEN's 30.52%. Bruce Berkowitz would check if strategic initiatives like cost cutting or better capital management explain the difference.
40.54%
Diluted EPS growth 1.25-1.5x AGEN's 30.52%. Bruce Berkowitz would verify if strategic moves (e.g., targeted acquisitions, cost cuts) explain the edge.
0.40%
Share reduction more than 1.5x AGEN's 4.44%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
0.40%
Diluted share reduction more than 1.5x AGEN's 4.44%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
No Data
No Data available this quarter, please select a different quarter.
51.97%
OCF growth 1.25-1.5x AGEN's 46.24%. Bruce Berkowitz would see if superior pricing or efficient operations explain the gap.
51.97%
FCF growth 1.25-1.5x AGEN's 45.59%. Bruce Berkowitz would see if capex decisions or cost controls create a cash flow advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both firms have negative 3Y CAGR. Martin Whitman would wonder if the entire market segment is in short-term retreat.
95.95%
10Y OCF/share CAGR above 1.5x AGEN's 61.93%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
79.78%
5Y OCF/share CAGR 1.25-1.5x AGEN's 71.91%. Bruce Berkowitz would see if capital spending or working-capital efficiencies explain the difference.
21.40%
3Y OCF/share CAGR at 75-90% of AGEN's 28.27%. Bill Ackman would press for improvements in margin or overhead to catch up.
95.64%
Net income/share CAGR 1.25-1.5x AGEN's 75.35%. Bruce Berkowitz might see more effective use of capital or consistently better margins over time.
74.54%
5Y net income/share CAGR 1.25-1.5x AGEN's 52.46%. Bruce Berkowitz would check if a better product mix or cost discipline explains the gap.
42.66%
3Y net income/share CAGR 50-75% of AGEN's 59.82%. Martin Whitman might see a lagging edge in short-term profitability vs. the competitor.
160.55%
Positive growth while AGEN is negative. John Neff might see a strong advantage in steadily compounding net worth over a decade.
2.24%
Below 50% of AGEN's 54.88%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
-69.25%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative 5Y dividend/share CAGR while AGEN stands at 0.00%. Joel Greenblatt sees a weaker commitment to dividends vs. a competitor that might be growing them.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-6.35%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-14.61%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-8.07%
We’re deleveraging while AGEN stands at 71.98%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-50.78%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
-4.70%
We cut SG&A while AGEN invests at 21.16%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.